Grant: Master's Award: Canada Graduate Scholarships
University of Manitoba
$17,500.00
Individual Variation in Inflammatory and Lipidomic Profiles of Obese Subjects in Response to Omega-3 Fatty Acids
EF 2017-18
Résumé
Obesity is characterized grade inflammation which contributes to obesity-associated diseases such as Type 2 Diabetes and cardiovascular disease. Omega-3 polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and α-linolenic acid (ALA) have demonstrated anti-inflammatory properties. However, comparisons between DHA and ALA have so far been performed only in healthy populations. Recent expert reviews have emphasized the need to personalize dietary interventions to accommodate genetic variance. In this project, we will compare the effects of DHA and ALA supplementation on inflammation and the effect of genetic variance on omega-3 metabolites. My hypothesis is that ALA and DHA supplementation will potently reduce inflammatory biomarkers associated with obesity and be associated with distinct alterations in metabolites, which will be influenced by geneticvariance in metabolic pathway enzymes. The overall aim(s) of my MSc is to determine 1) how ALA and DHA affect inflammation 2) how ALA and DHA affect metabolite profiles 3) to identify gene variants that contribute to both of these. Research delineating the effect of gene variants on the generation of metabolites from individual omega-3 PUFAs support the development of novel disease management strategies. Knowledge gained through investigating the impact of dietary nutrients and the identification of individual variation will enable the development of personalized anti-inflammatory diets. This, in turn, will offer a unique synergism with more traditional pharmacological approaches in treating obesity and its associated comorbidities.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386516
Name
Rodway Lisa A
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Individual Variation in Inflammatory and Lipidomic Profiles of Obese Subjects in Response to Omega-3 Fatty Acids
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Eicosanoids; Genetic Variants; Inflammation; Nutrition; Oxylipins; Polyunsaturated Fatty Acids; Single Nucleotide Polymorphisms
Abstract
Obesity is characterized grade inflammation which contributes to obesity-associated diseases such as Type 2 Diabetes and cardiovascular disease. Omega-3 polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and α-linolenic acid (ALA) have demonstrated anti-inflammatory properties. However, comparisons between DHA and ALA have so far been performed only in healthy populations. Recent expert reviews have emphasized the need to personalize dietary interventions to accommodate genetic variance. In this project, we will compare the effects of DHA and ALA supplementation on inflammation and the effect of genetic variance on omega-3 metabolites. My hypothesis is that ALA and DHA supplementation will potently reduce inflammatory biomarkers associated with obesity and be associated with distinct alterations in metabolites, which will be influenced by geneticvariance in metabolic pathway enzymes. The overall aim(s) of my MSc is to determine 1) how ALA and DHA affect inflammation 2) how ALA and DHA affect metabolite profiles 3) to identify gene variants that contribute to both of these. Research delineating the effect of gene variants on the generation of metabolites from individual omega-3 PUFAs support the development of novel disease management strategies. Knowledge gained through investigating the impact of dietary nutrients and the identification of individual variation will enable the development of personalized anti-inflammatory diets. This, in turn, will offer a unique synergism with more traditional pharmacological approaches in treating obesity and its associated comorbidities.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rodway, Lisa A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~